{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-455640","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-11-10T21:45:24+00:00","discovered_at":"2026-11-10T21:46:00.282749+00:00","generated_at":"2026-11-10T21:46:11.229071+00:00","sec_items":["3.03","1.01","2.01","5.02","9.01","2.02","3.02","5.03","5.01","5.05","5.06"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"InMed closes merger with Mentari; renamed Mentari Therapeutics (MTRI), Mentari holders own ~99%","bullets":["Closed Nov 6, 2026 merger: InMed became Mentari Therapeutics, ticker MTRI on Nasdaq, after 1-for-10 reverse split and redomestication from British Columbia to Nevada.","Exchange ratio was 0.20065 Company shares per Mentari common/Series A share; Mentari Series Seed preferred converted at 0.00020065 Company Series A preferred per share.","Post-close fully diluted: legacy InMed holders ~1.0%, Mentari holders ~99.0%, after $490.0M PIPE of 215,042,178 shares and 7,317,328 pre-funded warrants.","PIPE included $52.7M of principal/accrued interest on Mentari convertible notes; $290M tranche priced off $125M valuation, additional $200M at 152.8% of that price.","CVRs: one per InMed share held Nov 5, 2026, paying 100% of net proceeds from legacy InMed business sale in first year and 90% in second; 2-year term, extendable to 15 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-455640","json":"https://secwatch.observer/filing/0001193125-26-455640.json","markdown":"https://secwatch.observer/filing/0001193125-26-455640.md","text":"https://secwatch.observer/filing/0001193125-26-455640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/d539218d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:46:11.229071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c4b4923e3","claim":"Julianne Bruno was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm","confidence":0.5,"family_label":"Executive change","details":[{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"90cb1aaff0","claim":"Michelle Pernice was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm","confidence":0.5,"family_label":"Executive change","details":[{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"be7d4e6d7d","claim":"Laura Sandler was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm","confidence":0.5,"family_label":"Executive change","details":[{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e52f0c9f82","claim":"Todd Shegog was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm","confidence":0.5,"family_label":"Executive change","details":[{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}